Market, inquire medical diagnosis -- Ju Xian Pharmaceutical

The middle and high management is expected to stimulate the operation vitality with full shareholding

Governing control of xianju state-owned assets management company owns a 21.55% stake in fairy Ju pharmaceutical, is the first major shareholders and actual controllers company management team headed by chairman Jin Jingde majority stakes in 2001 restructuring of the transferee company, but since then the company newly introduced high management have not been able to achieve holding company on December 28, disclosure of non-public plan, headed by general manager Zhang Yusong all high management intends to participate in the three-year increases, will stimulate business rely on energy technology innovation from d.zingiberensis wight, 2015 release of profit elasticity

Steroids upstream raw materials turmeric is distribution in China only the most qinba - mount wudang area and other minority regions, by the turmeric planting and environmental constraints, extraction of diosgenin from d.zingiberensis wight, nearly three years and dienes prices rose sharply, seriously affected the company operating performance of 4 - new process route for years pr, AD 2015, will carry out large-scale industrial application, we expect 2014 dienes average purchase price is in 1.4 million yuan/ton, 4 - AD process routes of the new costs 900000 yuan/ton dienes, 4 - AD 100 tonnes per alternative dienes is expected to cost about 50 million

Core variety competition structure good, medium and long term growth clear progestin capsule is one of the largest item company agents, revenue of 147 million, 2013, the industry demand constantly release, future sales scale is expected to reach 500 million, we are expected to maintain 20% growth over the next three years the company and the interaction between rocuronium shun atracurium is core product, and muscle relaxants market muscle relaxant revenue of 162 million, 2013, the future is expected to achieve 30% compound growth companies in the field of anti asthma inhaler have the best of the domestic product line: thiamethoxam bromide aerosol ring SuoNaiDe aerosol

Furoic acid mo betamethasone nasal spray, dienes, epoxy progesterone, 16 - the DPA, in 2015 is expected to obtain approval documents GSK auxiliary ShuLiang generics prednisone acetate tablets progesterone injection generic drug products such as large amount of price is low, the future is expected to greatly benefit from the new national cheap medicine daily cost management policy companies operating point clear, the market value for the next three years the company's performance over the past three years have double space affected by double ene rises in price considerably, 4 - AD 2015 new process route after the large-scale industrial application will never jiu, get rid of dienes depend on larger contribution to the profit elasticity

Company has the very best xiu preparation product line, progesterone capsules and muscle relaxants anti asthma inhaler, etc are in good growth, a guarantee we expect continued growth for 2014-2016, the company implemented EPS0.10 yuan to 0.33 yuan to 0.47 yuan, rose to 15%, 223%, 45%, respectively is 101 and 31 times in 21 times earnings, the company is a typical inflection point type enterprise, to maintain overweight rating